PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
5.38 - 5.60
4.95 - 8.28
2.3K / 2.4K (Avg.)
-279.00 | -0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.49%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-7.01%
Negative gross profit growth while STERV.HE is at 6.47%. Joel Greenblatt would examine cost competitiveness or demand decline.
-11.66%
Negative EBIT growth while STERV.HE is at 28.07%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-11.66%
Negative operating income growth while STERV.HE is at 28.07%. Joel Greenblatt would press for urgent turnaround measures.
10.43%
Net income growth under 50% of STERV.HE's 22.77%. Michael Burry would suspect the firm is falling well behind a key competitor.
10.00%
EPS growth under 50% of STERV.HE's 23.68%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
10.00%
Diluted EPS growth under 50% of STERV.HE's 23.68%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.24%
Share change of 0.24% while STERV.HE is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.39%
Slight or no buyback while STERV.HE is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
2359.26%
OCF growth above 1.5x STERV.HE's 78.82%. David Dodd would confirm a clear edge in underlying cash generation.
125.27%
FCF growth 75-90% of STERV.HE's 152.38%. Bill Ackman might push for improved capital allocation or operational changes to match the competitor.
-14.44%
Negative 10Y revenue/share CAGR while STERV.HE stands at 9.98%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
35.92%
5Y revenue/share CAGR above 1.5x STERV.HE's 18.09%. David Dodd would look for consistent product or market expansions fueling outperformance.
32.32%
3Y revenue/share CAGR 1.25-1.5x STERV.HE's 23.36%. Bruce Berkowitz might see better product or regional expansions than the competitor.
37.33%
10Y OCF/share CAGR under 50% of STERV.HE's 157.86%. Michael Burry would worry about a persistent underperformance in cash creation.
-1.14%
Negative 5Y OCF/share CAGR while STERV.HE is at 57.69%. Joel Greenblatt would question the firm’s operational model or cost structure.
51.60%
3Y OCF/share CAGR 1.25-1.5x STERV.HE's 36.34%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
932.84%
Net income/share CAGR above 1.5x STERV.HE's 365.00% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
200.46%
5Y net income/share CAGR above 1.5x STERV.HE's 94.76%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
261.54%
3Y net income/share CAGR 50-75% of STERV.HE's 431.43%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
68.01%
10Y equity/share CAGR at 50-75% of STERV.HE's 117.77%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
77.29%
5Y equity/share CAGR at 50-75% of STERV.HE's 115.36%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
51.46%
3Y equity/share CAGR at 50-75% of STERV.HE's 81.66%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.48%
Inventory growth well above STERV.HE's 2.73%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
10.59%
Asset growth above 1.5x STERV.HE's 6.12%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
11.92%
1.25-1.5x STERV.HE's 10.02%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
0.61%
Debt shrinking faster vs. STERV.HE's 2.43%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
-27.51%
We cut SG&A while STERV.HE invests at 6.38%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.